Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data

por Cobble, Michael E, Frederich, Robert
Publicado 2012

A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic cont...

por White, Judith L, Buchanan, Patricia, Li, Jia, Frederich, Robert
Publicado 2014

Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus

por Karyekar, Chetan S, Ravichandran, Shoba, Allen, Elsie, Fleming, Douglas, Frederich, Robert
Publicado 2013

Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials

por Iqbal, Nayyar, Parker, Artist, Frederich, Robert, Donovan, Mark, Hirshberg, Boaz
Publicado 2014

The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial

por Frederich, Robert, McNeill, Robert, Berglind, Niklas, Fleming, Douglas, Chen, Roland
Publicado 2012

Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials

por Patel, Shrita, Hickman, Anne, Frederich, Robert, Johnson, Susan, Huyck, Susan, Mancuso, James P., Gantz, Ira, Terra, Steven G.
Publicado 2020

Efficacy and Safety of Ertugliflozin Added to Metformin: A Pooled Population from Asia with Type 2 Diabetes and Overweight or Obesity

por Ji, Linong, Liu, Jie, Xu, Zhi Jin, Wei, Zhiqi, Zhang, Ruya, Malkani, Seema, Cater, Nilo B., Frederich, Robert
Publicado 2023

Efficacy and Safety of Ertugliflozin in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea: A Sub-Study of VERTIS CV

por Budoff, Matthew J., Davis, Timothy M. E., Palmer, Alexandra G., Frederich, Robert, Lawrence, David E., Liu, Jie, Gantz, Ira, Derosa, Giuseppe
Publicado 2021

Heart and Kidney Outcomes With Ertugliflozin in People with Non-albuminuric Diabetic Kidney Disease: A post hoc Analysis from the Randomized VERTIS CV Trial

por Cherney, David Z.I., Dagogo-Jack, Samuel, Cosentino, Francesco, Pratley, Richard E., Frederich, Robert, Maldonado, Mario, Liu, Chih-Chin, Cannon, Christopher P.
Publicado 2022

Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV

por Dagogo-Jack, Samuel, Frederich, Robert, Liu, Jie, Cannon, Christopher P, Shi, Harry, Cherney, David Z I, Cosentino, Francesco, Masiukiewicz, Urszula, Gantz, Ira, Pratley, Richard E
Publicado 2023

Multiple Cytokines and Acute Inflammation Raise Mouse Leptin Levels: Potential Role in Inflammatory Anorexia

por Sarraf, Pasha, Frederich, Robert C., Turner, Ewa M., Ma, Grace, Jaskowiak, Nora T., Rivet, Dennis J., Flier, Jeffrey S., Lowell, Bradford B., Fraker, Douglas L., Alexander, H. Richard
Publicado 1997

Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose‐lowering agent: An analysis from VERTIS CV

por Dagogo‐Jack, Samuel, Cannon, Christopher P., Cherney, David Z. I., Cosentino, Francesco, Liu, Jie, Pong, Annpey, Gantz, Ira, Frederich, Robert, Mancuso, James P., Pratley, Richard E.
Publicado 2022

Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial

por Wojeck, Brian S., Inzucchi, Silvio E., Neeland, Ian J., Mancuso, James P., Frederich, Robert, Masiukiewicz, Urszula, Cater, Nilo B., McGuire, Darren K., Cannon, Christopher P., Yaggi, Henry Klar
Publicado 2022

Initial eGFR Changes with Ertugliflozin and Associations with Clinical Parameters: Analyses from the VERTIS CV Trial

por Cherney, David Z.I., Cosentino, Francesco, Dagogo-Jack, Samuel, McGuire, Darren K., Pratley, Richard E., Frederich, Robert, Maldonado, Mario, Liu, Chih-Chin, Pong, Annpey, Cannon, Christopher P.
Publicado 2022

Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial

por Cherney, David Z. I., Charbonnel, Bernard, Cosentino, Francesco, Dagogo-Jack, Samuel, McGuire, Darren K., Pratley, Richard, Shih, Weichung J., Frederich, Robert, Maldonado, Mario, Pong, Annpey, Cannon, Christopher P.
Publicado 2021

Kidney outcomes using a sustained ≥40% decline in eGFR: A meta‐analysis of SGLT2 inhibitor trials

por Cherney, David Z. I., Dagogo‐Jack, Samuel, McGuire, Darren K., Cosentino, Francesco, Pratley, Richard, Shih, Weichung J., Frederich, Robert, Maldonado, Mario, Liu, Jie, Wang, Shuai, Cannon, Christopher P.
Publicado 2021

Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter]

por Cherney, David Z. I., Charbonnel, Bernard, Cosentino, Francesco, Dagogo-Jack, Samuel, McGuire, Darren K., Pratley, Richard, Shih, Weichung J., Frederich, Robert, Maldonado, Mario, Pong, Annpey, Cannon, Christopher P.
Publicado 2022

Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized tri...

por Dagogo-Jack, Samuel, Pratley, Richard E, Cherney, David Z I, McGuire, Darren K, Cosentino, Francesco, Shih, Weichung J, Liu, Jie, Frederich, Robert, Mancuso, James P, Raji, Annaswamy, Gantz, Ira
Publicado 2021

Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials

por Cherney, David Z. I., Heerspink, Hiddo J. L., Frederich, Robert, Maldonado, Mario, Liu, Jie, Pong, Annpey, Xu, Zhi J., Patel, Shrita, Hickman, Anne, Mancuso, James P., Gantz, Ira, Terra, Steven G.
Publicado 2020

Cardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use: Post Hoc Analyses of the VERTIS CV Trial

por Cosentino, Francesco, Cannon, Christopher P., Frederich, Robert, Cherney, David Z.I., Dagogo-Jack, Samuel, Pratley, Richard E., Mancuso, James P., Maldonado, Mario, Cater, Nilo B., Wang, Shuai, McGuire, Darren K.
Publicado 2022